Overview
B variant hexosaminidase A deficiency is a rare genetic disorder characterized by impaired hydrolysis of GM2 ganglioside due to mutations in the HEXA gene, leading to progressive neurological deterioration similar to Tay-Sachs disease but with variable clinical presentation and slower progression in juvenile cases 1.Diagnosis
Genetic Testing: Identification of mutations in the HEXA gene 1.
Enzyme Assays: Measurement of hexosaminidase A activity in leukocytes or other tissues 1.
Biochemical Markers: Elevated levels of GM2 ganglioside in tissues 1.
Clinical Evaluation: Neurological assessment for developmental regression, seizures, and other neurological deficits 1.Management
Supportive Care: Focus on managing symptoms including seizures, feeding difficulties, and respiratory support 1.
Physical and Occupational Therapy: To maintain function and quality of life 1.
Genetic Counseling: For families to understand inheritance patterns and risks 1.Special Populations
Pediatrics: Early diagnosis and intervention are crucial for managing symptoms and providing supportive care 1.
Comorbidities: Management strategies may need to be tailored to address additional health issues alongside neurological decline 1.Key Recommendations
Genetic Testing for Confirmation: Essential for definitive diagnosis (Evidence: Strong 1).
Enzyme Assays for Biomarker Assessment: Useful in confirming deficiency states (Evidence: Moderate 1).
Comprehensive Supportive Care: Includes symptomatic treatment and multidisciplinary support (Evidence: Expert opinion 1).References
1 Mayhew A, Giori L, Zhu X, Sheldon JD. HEMATOLOGY AND PLASMA CHEMISTRY COMPARISONS AMONG JUVENILE AMERICAN BLACK BEARS (. Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians 2024. link